Addiction specialist expresses concern after FDA approves esketamine 07-Mar-2019 By Maggie Lynch US FDA approves esketamine nasal spray for treatment-resistant depression, addiction specialist cautions against its use.
Esketamine nasal spray for ‘debilitating mental illness’ recommended for approval 14-Feb-2019 By Maggie Lynch US FDA Psychopharmacologic Drug Advisory Committee recommends Spravato, an intranasal form of esketamine, for approval based on its favorable benefit-risk profile.